Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Ketamine has demonstrated rapid antidepressant effects in patients with treatment-resistant depression (TRD); however, the safety and tolerability of ketamine in this population have not been fully described. Herein we report the largest study to date of the safety, tolerability, and acceptability of ketamine in TRD. METHOD: Data from 205 intravenous (IV) ketamine infusions (0.5 mg/kg over 40 minutes) in 97 participants with DSM-IV-defined major depressive disorder (MDD) were pooled from 3 clinical trials conducted between 2006 and 2012 at 2 academic medical centers. Safety and tolerability measures included attrition, adverse events (AEs), hemodynamic changes, and assessments of psychosis and dissociation. RESULTS: The overall antidepressant response rate, defined as a ≥ 50% improvement in Montgomery-Asberg Depression Rating Scale score, was 67% (65 of 97 participants). Four of 205 infusions (1.95%) were discontinued due to AEs. The overall attrition rate was 3.1% (3 of 97). In the first 4 hours after the infusion, the most common general AEs were drowsiness, dizziness, poor coordination, blurred vision, and feeling strange or unreal. Approximately one third of individuals experienced protocol-defined hemodynamic changes. Ketamine resulted in small but significant increases in psychotomimetic and dissociative symptoms (all P < .05). There were no cases of persistent psychotomimetic effects, adverse medical effects, or increased substance use in a subgroup of patients with available long-term follow-up information. CONCLUSIONS: In this relatively large group of patients with TRD, ketamine was safe and well tolerated. Further research investigating the safety of ketamine in severe and refractory depression is warranted. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT00419003, NCT00548964, and NCT00768430.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Minimal clinical research supports these findings, suggesting that risks of dependency are extremely low when ketamine is administered in a medical setting [158-160]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [160]
In the citing paper
“Wan et al. [14] reported higher transient BP increases (peak increase of 19.6/13.4 mmHg based on 205 ketamine infusions) [14].”
From Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) · cites this paper as [14]
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Self-citationDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Self-citationZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Self-citation(2001) · PubMed · Cited by 780
Cited by
Items 201–229 of 229
Safety and Efficacy of Ketamine in Treatment-Resistant Depression (TRD)
Punukula, H. C., Sree, B. K., & Pratyusha, V. (2020) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2020.v64i02.029
Olazabal, N., Bustamante, S. E. Z., Madrazo, M. A., Osa, L., Tyrone, A. M. O. O., Catalán, A., & Torres, M. Á. G. (2021) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsm.2021.01.002
Evaluation of the antidepressant potential of dextromethorphan
Nguyen, L. (2015) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.6309
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_420-1 · Cited by 2
Zaccarelli‐Magalhães, J. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.10.2021.tde-16072021-104019 · Cited by 2
Nitrous Oxide: An Old Compound with Emerging Psychotropic Properties
Kamel, L. Y., Quach, D. F., Gott, B. M., & Conway, C. R. (2021) · Contemporary clinical neuroscience · doi:10.1007/978-3-030-79790-4_4
Paris, Église Saint Roch (Ier arrt), Tombeau de Madame de La Live de Jully par Falconet (1753)
Atget, E. (1927) · Appartient à un fonds de photographies vendu à l'Ecole des beaux-arts par Atget, seul photographe inscrit sous son nom dans les registres d'entrée des collections ; Numéro d'inventaire ENSBA : 38688
Peripheral biomarkers in Repeated Ketamine Infusions Trial
Geel, A. V. (2021) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2021-14775
Nontraditional therapies for treatment-resistant depression
Dokucu, M. E. (2021) · Current Psychiatry · doi:10.12788/cp.0166
Kaska, S., & Mazei‐Robison, M. S. (2016) · Wiley eBooks · doi:10.1002/9780470015902.a0025796
Management of ketamine-induced bilateral upper urinary tract injury
Rizvi, I. G., & Belal, M. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780198854371.003.0031
Schnell wirksame Antidepressiva
Şen, Z. D., Danyeli, L. V., & Walter, M. (2022) · Springer eBooks · doi:10.1007/978-3-662-65734-8_10
Geller, J. A., Keith, K. M., & Mischel, N. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001697
Pham, G. S., & Mathew, S. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18496-3.00014-8
Self-citationKetamine, Dissociation, and Depression: What Is “Special” About Ketamine? (Revisited)
Rizk, M., & Murrough, J. W. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae024 · Cited by 1
“For example, we analyzed a case series of 205 i.v. ketamine infusions in 97 adult participants with MDD and found that changes in CADSS score did not differ significantly between ketamine responders and nonresponders (Wan et al., 2015).”
MethodSelf-citationThe effectiveness of ketamine in medication of treatment-resistant depression - review
Brzozowska, P., Bulska, K., Sławek, K., Piela, A., Piotrowski, J., Hądzlik, I., Biały-Karbowniczek, J., Nowińska, B., Łuczak, B., & Słychan, K. (2024) · Quality in Sport · doi:10.12775/qs.2024.16.52628
“…of patients treated with ketamine, where long-term observation was carried out, there were no cases of unfavorable medical effects, persistence of psychomimetic effects, addiction to psychoactive substances, which could be observed to a small extent at the beginning of drug administration [23].”
BackgroundGillespie, C. F., & Nemeroff, C. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00046-7
Skoblenick, K. J., Yip, R., Khullar, A., McIntyre, R. S., & Swainson, J. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.02.026
Chrenek, C., & Swainson, J. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_12
Ketamine/esketamine for treatment-resistant depression
Nikayin, S., & Sanacora, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00013-x · Cited by 6
Ketamine toxicity: Translating preclinical findings to adverse effects in humans
Nezic, K., Ntafoulis, I., & Jacobs, G. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29930-8.00009-6
Sanspara, M. M., Shah, D., Shah, S. H., Desai, N. D., Shah, S., & Patel, P. S. (2025) · Indian Journal of Psychological Medicine · doi:10.1177/02537176251389117
“8,24,25 Studies by Krystal and Wan observed a slight dose-dependent increase in BP with IV Ketamine, 26,27 while we observed a decrease in BP with IM ketamine, although not significant.”
Ahuja, S., Brendle, M., Smart, L., Moore, C., Thielking, P. D., & Robison, R. J. (2022) · Figshare · doi:10.6084/m9.figshare.21268940
Ahuja, S., Brendle, M., Smart, L., Moore, C., Thielking, P. D., & Robison, R. J. (2022) · Figshare · doi:10.6084/m9.figshare.21268943
Lan, X., Liu, H., Wang, C., Li, W., Zhang, F., Hu, Z., Chen, X., You, Z., Ning, Y., & Zhou, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25107738
Fischer, M., & Abd-Elsayed, A. A. (2025) · Springer eBooks · doi:10.1007/978-3-032-10403-8_2
Treating addiction with an addictive drug: the ketamine paradox revisited
Hakami, A. Y. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1866092
Wasolua, T. T., Hardy, M. S., Bommersbach, T. J., McIntyre, R. S., & Rhee, T. G. (2026) · Psychotherapy and Psychosomatics · doi:10.1159/pps/aemag005 · Cited by 1
Feasibility and tolerability of virtual reality during esketamine treatment: A pilot study
Curran, E., Kumpf, K. T., Ansari, M., Baghaei, N., Elliott, T. C., Wilkinson, S. T., & Nikayin, S. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122554
Metadata
- Authors
- Wan, L.-B., Levitch, C. F., Perez, A. M., Brallier, J. W., Iosifescu, D. V., Chang, L. C., Foulkes, A., Mathew, S. J., Charney, D. S., & Murrough, J. W.
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2014-09-02
- Volume
- 76
- Issue
- 03
- Pages
- 247-252
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2059761623
- Cited by
- 231
- References
- 34
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 15 · 2023: 14 · 2022: 36 · 2021: 21 · 2020: 36 · 2019: 18 · 2018: 15 · 2017: 14 · 2016: 23 · 2015: 15 · 2014: 1
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000067)
- National Institute of Mental Health (R01MH081870, K23MH094707)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- ketamine, treatment-resistant depression, major depressive disorder, drug safety, tolerability, adverse events, psychotomimetic effects, dissociation, hemodynamic changes, antidepressant response, attrition, intravenous infusion
- MeSH terms
- Adult, Clinical Trials as Topic, Major Depressive Disorder, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Treatment Outcome, Excitatory Amino Acid Antagonists, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.